Twist Bioscience Launches Enzymatic Fragmentation Library Preparation Kit for High Uniformity, High-Yield Amplification, Streamlined Next Generation Sequencing Workflow for Targeted Applications

-- Efficient Library Preparation Prevents Wasted Samples --

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) today launched the Twist Library Preparation Enzymatic Fragmentation Kit 2.0, a robust all-in-one solution designed to maximize accuracy and efficiency in library construction and amplification when conducting next-generation sequencing (NGS). The kit is optimized for challenging NGS applications including liquid biopsy, somatic variant testing and genome-wide association studies. In addition, the kit excels in preparing samples where the amount of sample input DNA is either very limited or heavily degraded, as in the case of many banked oncology samples.

“Utilizing robust sample preparation technologies to generate sequencing libraries sets the stage for high-quality data and accurate results,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We’ve introduced this kit to enable our customers pursuing liquid biopsy, rare variants and other critical research to generate high-quality data consistently.”

The Library Preparation Enzymatic Fragmentation Kit 2.0 builds on Twist’s existing Library Preparation portfolio, giving customers more options when selecting a solution that works for their unique application or sample type. Combined with Twist’s industry-leading target enrichment panels that provide exceptional capture uniformity to avoid over-sequencing of areas outside the desired target regions, this new kit integrates a new amplification mix specifically developed for NGS applications.

“Twist continues to add innovative solutions to its expanding NGS portfolio to support researchers in a variety of disciplines. The introduction of these new tools showcases our ongoing commitment to the research and clinical communities, as we help them get to answers faster, deliver better outcomes and drive research forward,” continued Dr. Leproust.

About the Twist Library Preparation Enzymatic Fragmentation Kit 2.0

The Twist Library Preparation Enzymatic Fragmentation (EF) Kit 2.0 is a customized workflow to efficiently prepare samples that generate more accurate NGS results. The EF Kit 2.0 enables a streamlined workflow that combines library preparation steps into a single-tube reaction which, alongside a low chimera rate and Twist’s highly uniform target enrichment workflow, translates into high quality library preparation and NGS data.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including but not limited to the ability of the Twist Library Preparation Enzymatic Fragmentation Kit 2.0 to enable Twist customers pursuing liquid biopsy, rare variants and other critical research to generate high-quality data consistently, to obtain answers faster, to deliver better outcomes and to drive research forward, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on May 7, 2021 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.